Numerous preclinical studies have identified potential predictive biomarkers of EGFR inhibitor response in HNSCC including alterations in EGFR ligand expression levels [12–14], EGFR polymorphisms [15], EGFR variant III expression [16], nuclear EGFR [17], overexpression of other ErbB family receptors [18], MET activation [19], Axl overexpression [20], alterations in targets downstream of EGFR (e.g. PI3K, PTEN, src) [21] and FcγR SNPs [22]. Here, EGFR is linked to head and neck squamous cell carcinoma.